Article Details
Retrieved on: 2025-03-28 07:37:25
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses the variability in efficacy and safety of PCSK9 inhibitors for managing lipid metabolism disorders in high-risk ASCVD patients, contrasting monoclonal antibodies like evolocumab and alirocumab with inclisiran, with no direct link to diabetes.
Article found on: www.medicalrepublic.com.au
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here